Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Hacioglu, Muhammet; Kostek, Osman; Karabulut, Senem; Tastekin, Didem; SEZGİN GÖKSU, SEMA; Alandag, Celal; Akagunduz, Baran; Bilgetekin, Irem; Caner, BURCU; ŞAHİN, AHMET; Yildiz, Birol; Kose, Fatih; Kaplan, Muhammet; Gulmez, Ahmet; DOĞAN, ENDER; Guven, Deniz; Gurbuz, Mustafa; Ergun, Yakup; KARAAĞAÇ, MUSTAFA; Demiray, Atike; Turker, Sema; Sakalar, Teoman; Ozkul, Ozlem; Telli, Tugba; Sahin, Suleyman; KILIÇKAP, SAADETTİN; Bilici, Ahmet; ERDOĞAN, BÜLENT; ÇİÇİN, İRFAN

Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Copy For Citation

Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., ...More

JOURNAL OF BUON, vol.25, no.4, pp.1897-1903, 2020 (SCI-Expanded)

Publication Type: Article / Article
Volume: 25 Issue: 4
Publication Date: 2020
Journal Name: JOURNAL OF BUON
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
Page Numbers: pp.1897-1903
Bursa Uludag University Affiliated: Yes

Abstract

Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.